Samantha van Voorhis, APRN
Family · Norwich, CTNPI 1649976416
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,688 of the $15,582 with a category attached, or 75.0%. 37 manufacturers reported payments, led by Sanofi at 28.0% of the total. 2025 is the largest year on record at $8,661, 3.9 times the $2,209 reported in 2023. Among family clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 479 payments — averaging $32.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$4K
- GSK$2K
- AstraZeneca$2K
- Jazz Pharmaceuticals Inc.$664
- Harmony Biosciences LLC$601
- Actelion Pharmaceuticals US, Inc.$574
- plus $5K from 31 others
What the payments were for
- Consulting fees$2,52016%
- Travel & lodging$8255%
- Food & beverage$11,68875%
- Education$5494%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 25 | $4,357 |
| GSK | 109 | $2,144 |
| AstraZeneca(2 entities) | 56 | $1,801 |
| Jazz Pharmaceuticals Inc. | 15 | $664 |
| Harmony Biosciences LLC | 21 | $601 |
| Actelion Pharmaceuticals US, Inc. | 20 | $574 |
| Boehringer Ingelheim | 26 | $572 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $554 |
| Axsome Therapeutics, Inc. | 18 | $465 |
| Electromed, Inc. | 25 | $366 |
| Mallinckrodt Hospital Products Inc. | 15 | $353 |
| Verona Pharma, Inc. | 12 | $304 |
| Grifols USA, LLC | 10 | $262 |
| Insmed, Inc. | 12 | $259 |
| Philips North America LLC | 12 | $226 |
| Amgen | 10 | $219 |
| Baxter Healthcare | 9 | $205 |
| Mylan Specialty L.p. | 10 | $203 |
| Sanofi-aventis U.S. LLC | 2 | $195 |
| Viatris Specialty LLC | 8 | $155 |
| Regeneron Healthcare Solutions, Inc. | 7 | $135 |
| Pfizer | 5 | $135 |
| ZOLL Respicardia, Inc. | 2 | $121 |
| Genentech USA, Inc. | 4 | $112 |
| Inspire Medical Systems, Inc. | 2 | $106 |
| Lilly USA, LLC | 4 | $102 |
| Azurity Pharmaceuticals, Inc. | 4 | $85 |
| Optinose US, Inc. | 3 | $73 |
| Novartis | 2 | $69 |
| AbbVie | 2 | $36 |
| Merck | 1 | $27 |
| United Therapeutics Corporation | 1 | $23 |
| Vifor Pharma, Inc. | 1 | $19 |
| 3b Medical, Inc. | 1 | $17 |
| Phadia US Inc. | 1 | $16 |
| CSL Behring | 1 | $16 |
| Ambu Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,582 in reported general payments places this provider in the 95th percentile of 1,596 family providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 227 | $286,908 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 48 | $42,068 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $16,677 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $15,963 |
| SymbicortBudesonide/Formoterol Fumarate | 28 | $13,791 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 152 | $6,504 |
| Wixela InhubFluticasone Propion/Salmeterol | 18 | $3,468 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $2,315 |
| Ventolin HfaAlbuterol Sulfate | 12 | $1,872 |
| Roflumilast | 15 | $1,207 |
| Montelukast Sodium | 57 | $793 |
| Fluticasone Propionate | 30 | $618 |
| Prednisone | 155 | $526 |
| Azithromycin | 78 | $275 |
| Doxycycline Hyclate | 12 | $87 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $2,144 | $344,938298 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,801 | $30,46842 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,596 family providers in Connecticut.
Other family in Norwich
- Nicole McKenzieNorwich$16K
- Leonna WhiteNorwich$11K
- Stacy MarshNorwich$11K
- Elisha ChristiansonWaterbury$371K
- Kathryn TierneyNew Britain$140K
- Jennifer SilvaSouth Windsor$91K
- Carli WillardEnfield$74K
- Erin MartinMilford$70K
- Dayna GiordanoNew Haven$65K
- Diana BytyqiDerby$53K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.